Bharat Biotech pursues Covid-19 vaccine approval in over 40 countries
India's Bharat Biotech is in the process of
filing regulatory documents for approval of its COVID-19 vaccine, COVAXIN, in more than 40
countries, the company told Reuters late on Wednesday.
"We
have submitted our documentation in Brazil and other countries and await their
approval. We plan to export several million doses to Brazil," the company
said in an emailed statement. "Pricing of COVAXIN for international markets will be based upon supply
timelines, purchase commitments and procurement volumes," it added.
Bharat
Biotech, which last Tuesday had told Reuters it may export doses of COVAXIN to
Brazil and the United Arab Emirates by the end of the week, did not name other
countries and did not give exact figures on doses it expects to export.
The
company has also entered into an agreement with U.S. drug developer Ocugen Inc
for the commercialization of COVAXIN in the United States, which has seen the
most number of infections in the world. Read More
Comments
Post a Comment